Skip to main content
main-content

The independent medical news service

Melanoma

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

15-04-2020 | Oncology | News | Article

Long noncoding RNA signatures may help predict immunotherapy response

Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.

30-01-2020 | Oncology | News | Article

Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

13-11-2019 | Oncology | News | Article

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

24-09-2019 | Oncology | News | Article

Inflammatory arthritis persists post immune checkpoint inhibitor therapy

Immune checkpoint inhibitor-induced inflammatory arthritis among patients with cancer may need long-term management by rheumatologists after cessation of treatment, but does not appear to affect cancer outcomes, say researchers.

12-08-2019 | Oncology | News | Article

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

28-06-2019 | Oncology | News | Article

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

07-05-2019 | Oncology | News | Article

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

29-03-2019 | Oncology | News | Article

Flu vaccine not contraindicated for checkpoint inhibitor-treated cancer patients

A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.

30-10-2018 | Oncology | News | Article

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

18-10-2018 | Melanoma | News | Article

Neoadjuvant checkpoint blockade investigated in high-risk melanoma

In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.

14-09-2018 | Oncology | Main feed | News

EMA supports encorafenib plus binimetinib combination

Read more here

07-09-2018 | Melanoma | News | Article

FDG-PET predicts metastatic melanoma outcomes better than CT imaging

Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

10-08-2018 | Oncology | News | Article

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

17-07-2018 | Melanoma | News | Article

‘Dramatically improved’ OS with checkpoint inhibitor use for melanoma brain metastases

Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.

12-07-2018 | Oncology | News | Article

High glucocorticoid doses may negatively impact CTLA-4 inhibitor efficacy

Researchers recommend against the routine use of high-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis inpatients with melanoma after observing poorer oncologic outcomes with high versus low doses.

05-07-2018 | Oncology | News | Article

Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

Find out more about this US FDA decision here

18-06-2018 | Melanoma | News | Article

COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

Image Credits